Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
_256_384.jpg)
Mesalazine is used to treat inflammatory bowel disease
ALS patients experience neuroinflammation and rapid neurodegeneration
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of US $34.7 million in the United States
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
Subscribe To Our Newsletter & Stay Updated
